FDA Rejects AL001 Bipolar Trial Design; MGH Terminates BD Study Work
ALZN sits 32% above its 52-week low of $0.84 on light trading volume (0.3× avg).
Summary
The FDA rejected Alzamend's bipolar-disorder trial design as inadequate for approval, and on November 11, 2026 MGH terminated the related study work. The company now plans a Type B meeting to propose skipping Phase II for a Phase III trial, with FDA feedback not expected until the end of Q2 2027.
Key Events · Product Development and Regulatory · ALZN
-
FDA Rejects Bipolar Trial Design
In written feedback dated October 15, 2026, the FDA said the proposed trials did not appear designed as adequate and well-controlled studies capable of providing substantial evidence of effectiveness.
-
MGH Terminates BD Study Work
After the company paused the BD Clinical Trial on October 21, 2026, MGH delivered written notice on November 11, 2026 terminating the BD statement of work and reassigning staff; Alzamend will receive a refund of approximately $25,000 in unused funds.
-
Phase III Pivot Proposed
Alzamend intends to request a Type B meeting to propose ceasing Phase II trials of AL001 and moving directly into a Phase III efficacy and safety trial in bipolar disorder supporting an NDA.
-
FDA Feedback Slips to Mid-2027
The company is preparing a briefing package and currently anticipates receiving FDA feedback by the end of the second quarter of 2027.
Analysis · ALZN · Life Sciences
Alzamend's bipolar-disorder program has lost its regulatory footing: the FDA said the proposed trial design would not yield the adequate and well-controlled evidence needed for approval, and Massachusetts General Hospital has now walked away from the study entirely. That leaves no active bipolar trial, a plan to leap straight to a Phase III that regulators have not yet agreed to, and a timeline pushing any FDA feedback to the end of the second quarter of 2027. For a company already carrying going-concern doubt, the nearest source of clinical news is gone and the path to an NDA stretches by well over a year, leaving only the December 2026 healthy-volunteer results as a near-term readout.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALZN was trading at $1.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.84 to $2.56. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.